General Information of Drug (ID: DM5VH6U)

Drug Name
Serlopitant Drug Info
Synonyms
VPD-737; UNII-277V92K32B; CHEMBL447955; 860642-69-9; 277V92K32B; 3-((3aR,4R,5S,7aS)-5-((R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(4-fluorophenyl)hexahydro-1H-isoindol-2(3H)-yl)cyclopent-2-enone; Serlopitant [USAN:INN]; VPD 737; Serlopitant (USAN); SCHEMBL3183159; GTPL9280; mk-0594; FLNYCRJBCNNHRH-OIYLJQICSA-N; BDBM50277511; compound 17 (Jiang et al. 2009); DB12973; D09378; 3-[(3aR,4R,5S,7aS)-5-{(1R)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy}-4-(4-fluorophenyl)octahydro-1H-isoindol-2-yl]cyclopent-2-en-1-one
Indication
Disease Entry ICD 11 Status REF
Prurigo nodularis EC91.0 Phase 3 [1]
Psoriasis vulgaris EA90 Phase 2 [1]
Cross-matching ID
PubChem CID
23653789
CAS Number
CAS 860642-69-9
TTD Drug ID
DM5VH6U

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Substance-P receptor (TACR1) TTZPO1L NK1R_HUMAN Antagonist [1]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Substance-P receptor (TACR1) DTT TACR1 3.597 4.186 4.271 5.113
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Prurigo nodularis
ICD Disease Classification EC91.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Substance-P receptor (TACR1) DTT TACR1 7.40E-01 0.02 0.07
Substance-P receptor (TACR1) DTT TACR1 8.57E-01 -0.02 -0.18
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)